Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT

Rohtesh S. Mehta, Rima M. Saliba, Amin M. Alousi, Gheath Alatrash, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, Issa F. Khouri, Yago Nieto, Betul Oran, Uday R. Popat, Muzaffar H. Qazilbash, Jeremy L. Ramdial, Gabriela Rondon, Samer A. Srour, Katy Rezvani, Richard E. Champlin, Elizabeth J. Shpall, Kai Cao

Blood (2022) 140 (Supplement 1): 4880–4881.

https://doi.org/10.1182/blood-2022-158689

Published: 2022

Journal Articles

Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis

Rohtesh S. Mehta, Rima M. Saliba, Amin M Alousi, Gheath Alatrash, Qaiser Bashir, Partow Kebriaei, Issa F. Khouri, Yago Nieto, Betul Oran, Uday R Popat, Muzaffar H Qazilbash, Jeremy L. Ramdial, Gabriela Rondon, Samer A Srour, Katy Rezvani, Richard E Champlin, Elizabeth J Shpall, Kai Cao

Blood (2022) 140 (Supplement 1): 10530–10531.

https://doi.org/10.1182/blood-2022-166472

Published: 2022

Journal Articles

Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis

Rohtesh S. Mehta, Rima M. Saliba, Amin M Alousi, Gheath Alatrash, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, Issa F. Khouri, Yago Nieto, Betul Oran, Uday R Popat, Muzaffar H Qazilbash, Jeremy L. Ramdial, Gabriela Rondon, Samer A Srour, Katy Rezvani, Richard E Champlin, Elizabeth J Shpall, Kai Cao

Blood (2022) 140 (Supplement 1): 7649–7650.

https://doi.org/10.1182/blood-2022-166381

Published: 2022

Journal Articles

Mismatch in Sirpα, a Regulatory Protein in Innate Immunity, Is Associated with Outcomes of Allogeneic Stem Cell Transplantation for Lymphoid Malignancies

Rima M. Saliba, Uri Greenbaum, Qing Ma, Samer A. Srour, Gabriela Rondon, Elizabeth J. Shpall, Kai Cao, Richard E. Champlin, Jun Zou

Blood (2021) 138 (Supplement 1): 1804.

https://doi.org/10.1182/blood-2021-150926

Published: 2021

Journal Articles

Haploidentical Mbil-21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients with Multiple Relapsed and Refractory Acute Myeloid Leukemia

Stefan O. Ciurea, MD, Jolie Schafer, Piyanuch Kongtim, MD, Julianne Chen, Doris Soebbing, Kai Cao, MS, MD, Samer A. Srour, MD MS, Elizabeth J. Shpall, MD, Marina Konopleva, MD PhD, Dean Anthony Lee, MD PhD, Richard E. Champlin, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-134858

Published: 2020

Journal Articles

Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients

Betul Oran, MDMS, Richard E. Champlin, MD, Feng Wang, PhD, Nikeshan Jeyakumar, MD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Rima M. Saliba, PhD, Kai Cao, MS, MD, Elizabeth J. Shpall, MD, Amin M. Alousi, MD, Rohtesh S. Mehta, MD, Uday Popat, MD, Andy Futreal, PhD, Koichi Takahashi, MD

Blood (2019) 134 (Supplement_1): 47.

https://doi.org/10.1182/blood-2019-127195

Published: 2019

Journal Articles

Improved Outcomes for Patients Receiving High-Doses of IL-21 Ex Vivo Expanded NK Cells after Haploidentical Transplantation (haploSCT): Long-Term Follow-up of a Phase 1/2 Clinical Trial with Comparison to CIBMTR Controls

Stefan O. Ciurea, MD, Roland Bassett, Doris Soebbing, Gabriela Rondon, MD, Kai Cao, MS, MD, Amanda L. Olson, MD, Qaiser Bashir, MBBS, Elizabeth J. Shpall, MD, Steven Devine, Marcelo C. Pasquini, MD, Andrew St. Martin, MS, Dean Anthony Lee, MD PhD, Richard E Champlin

Blood (2019) 134 (Supplement_1): 700.

https://doi.org/10.1182/blood-2019-123936

Published: 2019

Journal Articles

Is a Matched Unrelated Donor Search Needed for All Allogeneic Transplant Candidates?

Blood (2018) 132 (Supplement 1): 3450.

https://doi.org/10.1182/blood-2018-99-111606

Published: 2018

Journal Articles

Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation after Double Cord Blood Transplantation

Blood (2018) 132 (Supplement 1): 2077.

https://doi.org/10.1182/blood-2018-99-114407

Published: 2018

Journal Articles

Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion

Blood (2018) 131 (11): 1248–1257.

https://doi.org/10.1182/blood-2017-07-798751

Published: 2018

Includes: Supplemental data

Journal Articles

Interim Results of a Phase 2 Clinical Trial Using Mb-IL21 Ex Vivo Expanded NK Cells to Enhance Graft Versus Leukemia Effect for Patients with Myeloid Malignancies after Haploidentical Transplantation

Stefan O. Ciurea, Doris Soebbing, Gabriela Rondon, MD, Kai Cao, MS, MD, Gheath Alatrash, DO, PhD, Sairah Ahmed, Uday Popat, MD, Betul Oran, MDMS, Qaiser Bashir, MD MBBS, Partow Kebriaei, MD, Indreshpal Kaur, PhD, Katayoun Rezvani, MD PhD, Elizabeth J Shpall, MD, Dean Anthony Lee, MD PhD, Richard E. Champlin, MD

Blood (2017) 130 (Supplement 1): 3179.

https://doi.org/10.1182/blood.V130.Suppl_1.3179.3179

Published: 2017

Journal Articles

Phase 1 clinical trial using mbIL21 ex vivo–expanded donor-derived NK cells after haploidentical transplantation

Stefan O. Ciurea, Jolie R. Schafer, Roland Bassett, Cecele J. Denman, Kai Cao, Dana Willis, Gabriela Rondon, Julianne Chen, Doris Soebbing, Indreshpal Kaur, Alison Gulbis, Sairah Ahmed, Katayoun Rezvani, Elizabeth J. Shpall, Dean A. Lee, Richard E. Champlin

Blood (2017) 130 (16): 1857–1868.

https://doi.org/10.1182/blood-2017-05-785659

Published: 2017

Includes: Supplemental data

Journal Articles

KIR gene haplotype: an independent predictor of clinical outcome in MDS patients

Blood (2016) 128 (24): 2819–2823.

https://doi.org/10.1182/blood-2016-05-713099

Published: 2016

Includes: Supplemental data

Journal Articles

Safety and Feasibility of Administration of High Doses of Ex Vivo Expanded NK Cells for Prevention of Disease Relapse after Transplantation for Patients with Myeloid Malignancies - Final Results of a Phase I Clinical Trial

Blood (2016) 128 (22): 500.

https://doi.org/10.1182/blood.V128.22.500.500

Published: 2016

Journal Articles

Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation

Blood (2016) 128 (2): 297–312.

https://doi.org/10.1182/blood-2016-03-706317

Published: 2016

Includes: Supplemental data

Journal Articles

Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation Following Reduced Intensity Conditioning Regimens

Blood (2015) 126 (23): 1190.

https://doi.org/10.1182/blood.V126.23.1190.1190

Published: 2015

Journal Articles

Phase I Trial of IL-21 Ex Vivo Expanded NK Cells Administration to Prevent Disease Relapse after Haploidentical Stem-Cell Transplantation for Myeloid Leukemias

Stefan O. Ciurea, MD, Dean A. Lee, MD PhD, Kai Cao, MS, MD, Gabriela Rondon, MD, Julianne Chen, Dana B. Willis, Sairah Ahmed, MD, Eric Yvon, PhD, Katayoun Rezvani, MDPhD, Elizabeth J. Shpall, MD, Richard E. Champlin, MD

Blood (2015) 126 (23): 102.

https://doi.org/10.1182/blood.V126.23.102.102

Published: 2015

Journal Articles

Increased Disease Progression in HLA-a, -B, -C, -DRB1 and -DBP1 Matched Recipients of Unrelated Donor Transplants with Peripheral Blood Is Independent of Risk Groups By Disease Risk Index

Betul Oran, MD, Rima M Saliba, PhD, Yudith Carmazzi, Elizabeth J. Shpall, MD, Katayoun Rezvani, MD, PhD, Marcos De Lima, MD, Marcelo Fernández-Viña, Richard E. Champlin, MD, Kai Cao, MS, MD

Blood (2015) 126 (23): 2005.

https://doi.org/10.1182/blood.V126.23.2005.2005

Published: 2015

Journal Articles

Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation

Blood (2015) 126 (23): 152.

https://doi.org/10.1182/blood.V126.23.152.152

Published: 2015

Journal Articles

Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study

Blood (2015) 126 (23): 929.

https://doi.org/10.1182/blood.V126.23.929.929

Published: 2015

NARROW

HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT

Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis

Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis

Mismatch in Sirpα, a Regulatory Protein in Innate Immunity, Is Associated with Outcomes of Allogeneic Stem Cell Transplantation for Lymphoid Malignancies

Haploidentical Mbil-21 Ex Vivo Expanded NK Cells (FC21-NK) for Patients with Multiple Relapsed and Refractory Acute Myeloid Leukemia

Donor Clonal Hematopoiesis Increases Risk of Acute Graft Versus Host Disease after Matched Related Transplantation in AML and MDS Patients

Improved Outcomes for Patients Receiving High-Doses of IL-21 Ex Vivo Expanded NK Cells after Haploidentical Transplantation (haploSCT): Long-Term Follow-up of a Phase 1/2 Clinical Trial with Comparison to CIBMTR Controls

Is a Matched Unrelated Donor Search Needed for All Allogeneic Transplant Candidates?

Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation after Double Cord Blood Transplantation

Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion

Interim Results of a Phase 2 Clinical Trial Using Mb-IL21 Ex Vivo Expanded NK Cells to Enhance Graft Versus Leukemia Effect for Patients with Myeloid Malignancies after Haploidentical Transplantation

Phase 1 clinical trial using mbIL21 ex vivo–expanded donor-derived NK cells after haploidentical transplantation

KIR gene haplotype: an independent predictor of clinical outcome in MDS patients

Safety and Feasibility of Administration of High Doses of Ex Vivo Expanded NK Cells for Prevention of Disease Relapse after Transplantation for Patients with Myeloid Malignancies - Final Results of a Phase I Clinical Trial

Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation

Ex Vivo Mesenchymal Precursor Cell-Expanded Cord Blood Transplantation Following Reduced Intensity Conditioning Regimens

Phase I Trial of IL-21 Ex Vivo Expanded NK Cells Administration to Prevent Disease Relapse after Haploidentical Stem-Cell Transplantation for Myeloid Leukemias

Increased Disease Progression in HLA-a, -B, -C, -DRB1 and -DBP1 Matched Recipients of Unrelated Donor Transplants with Peripheral Blood Is Independent of Risk Groups By Disease Risk Index

Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation

Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only